32 completed, 2 active not recruiting, 2 unknown. 12 Phase 3, 8 Phase 4, 6 Phase 1, 3 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 12 |
| Phase 4 | 8 | Completed 6, Unknown 2 |
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 2 | Completed 2 |
Follow Glipizide: new trials by email Literature Review of Glipizide trials Research Report on Glipizide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer Glipizide - Pancreatic Cancer, Pancreatic Carcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 29 | 2023-12-05 | 2026-08-06 |
| Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers Glucotrol XL 5Mg Extended-Release Tablet, Glipizide ER 5 MG 24 HR Extended Release Oral Tablet, Rifaximin 200Mg Tab - Human Gastrointestinal Physiology Data | Phase 1 | Completed | University of Michigan | 30 | 2022-03-15 | 2026-07-20 |
| Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA - Cardiovascular Events, Type2 Diabetes | Active not recruiting | Brigham and Women's Hospital | 781430 | 2021-08-01 | 2026-08-13 | |
| Comparison of Type 2 Diabetes Pharmacotherapy Regimens SU, DPP4, SGLT2i - Type 2 Diabetes Mellitus, Cardiovascular Diseases | Completed | Kaiser Permanente | 241981 | 2021-07-01 | 2025-11-21 | |
| Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes Sulfonylurea - Maturity-Onset Diabetes of the Young, Type 3, Maturity Onset Diabetes of the Young, Type 1 | Phase 4 | Unknown | Haukeland University Hospital | 30 | 2017-04-18 | 2020-01-27 |
| Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration Dapagliflozin, Metformin, Glipizide 5 MG - Diabetes Mellitus, Type 2 | Phase 4 | Completed | The University of Texas Health Science Center at San Antonio | 72 | 2016-12-20 | 2023-11-30 |
| Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management Linagliptin, Glipizide - Chronic Kidney Diseases, Type 2 Diabetes | Not applicable | Completed | University of Washington | 3 | 2015-11-01 | 2018-10-12 |
| Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Glipizide XL, Saxagliptin + Metformin XR, Metformin XR - Diabetes Mellitus Type 2, Hyperglycemia | Phase 4 | Completed | Cook County Health | 100 | 2014-09-09 | 2023-06-26 |
| Incretin-based Drugs and the Risk of Heart Failure DPP-4 inhibitors, GLP-1 analogs, Insulins - Type 2 Diabetes Mellitus | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1499650 | 2014-03-01 | 2016-04-19 | |
| Incretin-based Drugs and Acute Pancreatitis DPP-4 inhibitors, GLP-1 analogs, Insulins - Diabetes Mellitus, Type 2 | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1417914 | 2014-03-01 | 2016-11-03 | |
| Incretin-based Drugs and Pancreatic Cancer DPP-4 inhibitors, GLP-1 analogs, Sulfonylureas - Diabetes Mellitus, Type 2 | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 886172 | 2014-03-01 | 2016-03-14 | |
| Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Glipizide, Acarbose - Type 2 Diabetes | Phase 4 | Unknown | Shanghai Jiao Tong University School of Medicine | 160 | 2012-12-01 | 2013-01-01 |
| A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) Omarigliptin, Placebo to omarigliptin, Glipizide - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 213 | 2012-10-02 | 2018-08-09 |
| Effect of Exenatide on Liver and Heart Fat and Inflammation Exenatide, Glipizide - Type 2 Diabetes Mellitus | Phase 4 | Completed | Baylor College of Medicine | 24 | 2010-04-01 | 2016-05-16 |
| To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies Canakinumab 150 mg, Placebo to Canakinumab - Type 2 Diabetes Mellitus, Impaired Glucose Tolerance | Phase 2 | Completed | Novartis | 246 | 2010-02-01 | 2011-09-05 |
| Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects Glipizide - Genotype, Pharmacokinetic | Not applicable | Completed | Chinese Academy of Sciences | 14 | 2009-11-01 | 2010-03-09 |
| Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients AZD1656, Placebo, Glipizide - Type II Diabetes Mellitus | Phase 2 | Completed | AstraZeneca | 530 | 2009-10-01 | 2012-11-26 |
| Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128) Sitagliptin, Comparator: Placebo, Pioglitazone - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 313 | 2009-04-15 | 2017-05-23 |
| Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus Alogliptin, Metformin, Glipizide - Type 2 Diabetes Mellitus | Phase 3 | Completed | Takeda | 2639 | 2009-03-01 | 2013-12-03 |
| Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics Alogliptin, Glipizide - Diabetes Mellitus | Phase 3 | Completed | Takeda | 441 | 2008-06-01 | 2013-05-24 |
Showing 20 of 36. Sign in to see all of them.
Diabetes Mellitus, Type 2 (28) · Diabetes Mellitus (3) · Hyperglycemia (3) · Renal Insufficiency, Chronic (3) · Glucose Intolerance (2) · Pancreatic Neoplasms (2) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Diabetes Mellitus, Type 1 (1) · Dyslipidemias (1) · Glucose Metabolism Disorders (1) · Heart Failure (1) · Hyperinsulinism (1) · Kidney Diseases (1)
Merck Sharp & Dohme LLC (8) · Canadian Network for Observational Drug Effect Studies, CNODES (3) · AstraZeneca (2) · Cook County Health (2) · Mylan Pharmaceuticals Inc (2) · Sandoz (2) · Shanghai Jiao Tong University School of Medicine (2) · Takeda (2) · Baylor College of Medicine (1) · Brigham and Women's Hospital (1) · Chinese Academy of Sciences (1) · GlaxoSmithKline (1) · Haukeland University Hospital (1) · Kaiser Permanente (1) · Massachusetts General Hospital (1)
United States (16) · Canada (6) · Germany (5) · Mexico (5) · China (4) · India (4) · Italy (4) · Poland (4) · Argentina (3) · Hungary (3) · Latvia (3) · Peru (3) · Romania (3) · Russia (3) · South Africa (3)
Pierre Ernst, MD, MSc (3) · James D Carlson, Pharm. D. (2) · Roger D. Anderson, M.D. (2) · Ambika Babu, MD,MS (1) · Azeez Farooki, MD (1) · Bruno Jolain (1) · Cathrin Ring (1) · Da F Zhong, PH.D (1) · Elisabetta Patorno, MD, DrPH (1) · Eva Johnsson (1) · Guang Ning, M.D. Ph.D. (1) · Guang Ning, MD. PHD (1) · Ian de Boer, MD (1)
PMID 20194881, PMID 20456211, PMID 21477878, PMID 21816980, PMID 22742523, PMID 23116881, PMID 23230096, PMID 23248197, PMID 23352379, PMID 23529570, PMID 25633134, PMID 25812009, PMID 26888382, PMID 27007958, PMID 27479930, PMID 27787778, PMID 28449320, PMID 29326107, PMID 31709648, PMID 37798422, PMID 38745886, PMID 40270326, PMID 40734551, PMID 41091469
2008 (2)